Comparative Pharmacology
Head-to-head clinical analysis: HEXADROL versus HYDROCORTISONE IN ABSORBASE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HEXADROL versus HYDROCORTISONE IN ABSORBASE.
HEXADROL vs HYDROCORTISONE IN ABSORBASE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic glucocorticoid that binds to the glucocorticoid receptor, leading to regulation of gene expression and suppression of inflammatory cytokines, immune response, and adrenal function.
Glucocorticoid receptor agonist that modulates gene expression, leading to anti-inflammatory, immunosuppressive, and vasoconstrictive effects.
Adult: 0.75-9 mg/day orally in divided doses every 6-12 hours; IV/IM: initial 0.5-9 mg/day in divided doses every 6-12 hours.
Topical: Apply a thin layer to affected area 2-4 times daily.
None Documented
None Documented
Terminal elimination half-life: 36-54 hours; prolonged in hepatic impairment (up to 72 hours) due to reduced clearance.
Terminal elimination half-life: 1-2 hours (plasma cortisol); biological half-life (duration of action) 8-12 hours due to intracellular receptor effects.
Primarily renal: ~65-80% as unchanged drug and metabolites via glomerular filtration, with tubular reabsorption; minor biliary/fecal (5-10%).
Renal: primarily as 17-hydroxycorticosteroids and 17-ketosteroids; <5% unchanged. Biliary/fecal: minimal. Metabolites conjugated with glucuronide or sulfate.
Category C
Category D/X
Corticosteroid
Corticosteroid